

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Protocol and rationale for the International PANS Registry (IPR; pediatric acute onset neuropsychiatric syndrome)

Erin E. Masterson, PhD, MPH ^{1*}

Jessica M. Gavin, BA ²

¹ Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, Washington, U.S.A.

² Pediatric Research & Advocacy Initiative, Midlothian, Virginia, U.S.A.

*Corresponding Author:

Erin E. Masterson, PhD, MPH

University of Washington

Roosevelt One Building

4225 Roosevelt Way NE

Seattle, WA 98105

emaster@uw.edu

630-254-4183

Abstract

The International PANS Registry (IPR) is the first centralized, epidemiologic database of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and PANS-like features and their siblings. PANS is a relatively new umbrella syndrome that lacks diagnostic biomarkers and is characterized by a set of working criteria. The failure to find a diagnostic biomarker is likely due to underpowered studies and inherent biological heterogeneity within PANS. Until the IPR was established, a critical barrier to large-scale longitudinal studies had been the absence of a large-scale epidemiologic study and a centralized database of children with PANS and PANS-like features. The IPR was created to serve as a translational health tool to accelerate research on the broad spectrum of complex pediatric neuroimmune conditions with the long-term goal of enabling a paradigm shift in this field from symptom-based evaluation and treatment towards biology-based diagnoses, treatments, screening, and surveillance. To date, the IPR has registered 1,666 families (3,247 children) and is the largest database in the world that gathers in-depth information on children with PANS and PANS-like features and their siblings. Enrollment in the IPR is open and ongoing; longitudinal follow up is planned. Participating families enroll their children with PANS and PANS-like features and their healthy siblings in the IPR via an online survey platform. The selection criteria for IPR enrollment are intentionally less restrictive than the current working criteria for PANS to generate a large recruitment pool and enable study of the broad spectrum of PANS-like conditions. The IPR is designed to enable ancillary study recruitment based on detailed selection criteria and to grow and expand in scope in the future. The IPR team is committed to data sharing and invites collaborators who will leverage existing data from the IPR database and extend knowledge in an area beyond the original scope of the IPR.

Introduction

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is relatively newly defined and is a diagnosis of exclusion, characterized by acute onset of Obsessive-Compulsive Disorder (OCD) and/or severely-restricted food intake and at least two other neuropsychiatric symptoms in previously healthy children (1–4). These may include anxiety, emotional lability, irritability/aggression, behavioral regression, deterioration in school performance, sensory and/or motor abnormalities, and somatic signs and symptoms (1). Importantly, PANS does not have a validated diagnostic biomarker or ICD-11 diagnostic code (5). PANS is currently diagnosed using non-validated working criteria, putting patients at risk of misdiagnosis, delayed treatment, or inappropriate therapeutic intervention. In some cases, long-term psychiatric and neurological impairment; academic, developmental and behavioral regression; and severe social and emotional disruption to patients and their families may occur (4,6–10). The failure to find a diagnostic biomarker is likely due to underpowered studies and inherent biological heterogeneity within PANS.

A leading hypothesis is that the illness is driven by a brain-reactive autoimmune or neuroinflammatory response to infection (4,6,11). PANS is likely an umbrella syndrome comprised of subgroups (7,12), the most well-known of which is Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) (13–15). PANS and PANDAS patients tend to experience relapsing episodes of severe neuropsychiatric symptoms (16), but prospective studies testing for temporal correlations between symptoms and infection have yielded conflicting results—likely owing to small sample size (17,18). While some larger observational case-control studies support an association between infection and PANDAS (19), intra-individual analyses have not been possible. PANS has been observed in siblings and family clusters, suggesting genetic and/or environmental subtypes of PANS (20–23). Indeed, rare variant and genotype studies support a genetic basis for at least some subgroups of PANS (24,25). Furthermore, it is possible that PANS etiology may be connected to the prenatal environment, related to maternal immune health (25–28).

Until recently, a critical barrier to large-scale longitudinal studies had been the absence of a standardized, central database of PANS patients. The University of Washington’s (UW) International PANS Registry, launched on July 19, 2020, has registered 1,666 families (3,247 children) to date and is the largest database in the world that gathers in-depth

It is made available under a [CC-BY 4.0 International license](#) .

65 information on children with PANS and PANS-like features and their siblings.(29) The IPR fulfills a long-standing call in
66 the clinical and scientific communities for large-scale epidemiologic study and a centralized registry for children with
67 PANS and PANS-like features (4). The IPR was created to serve as a centralized hub of information and translational
68 health tool to accelerate research on the broad spectrum of PANS-like conditions with the long-term goal of enabling a
69 paradigm shift in this field from symptom-based evaluation and treatment towards biology-based diagnoses,
70 treatments, screening, and surveillance. The IPR was designed to expand globally and grow so as to represent a large
71 and diverse participant pool, to enable longitudinal studies, and to serve as a recruitment tool for clinical trials and
72 subsequent, ancillary studies—particularly those focused on more homogenous subgroups. Ultimately, the IPR aims to
73 improve diagnosis and accelerate therapeutic discovery by facilitating large-scale biomarker discovery and mechanistic
74 research of this complex illness, including identifying underlying subgroups and their dimensions.

76 **Methods and analysis**

77 **Study design**

78 The International PANS Registry (IPR; www.pansregistry.org)(29) is an open patient registry housed at the University of
79 Washington (UW), established in 2020 and sponsored by the Pediatric Research & Advocacy Initiative (PRAI), a 501(c)3
80 parent-led organization (29,30). The IPR is the first large-scale, epidemiological database in the world for PANS and
81 related neuroimmune conditions. The IPR was also designed to be able to expand globally and grow so as to represent a
82 diverse and sizeable participant pool, to enable longitudinal follow up, and to serve as a recruitment tool for subsequent
83 studies. All participants have consented to be followed longitudinally and to receive invitations to participate in
84 subsequent and/or ancillary studies. To date, the IPR data is observational, survey data based on parent report and
85 includes cases and healthy siblings, who we do *not* consider as study controls. Future goals include linking existing data
86 to ancillary studies and expanding the scope of included data elements by enrolling study controls, integrating pointed
87 medical record information, and creating a linked biobank to enable the evaluation of potential disease biomarkers and
88 genetic information.

89

90 **Patient and public involvement**

91 The IPR is a collaborative community-based research partnership between the two authors, an epidemiologist (EEM) and
92 the director of the PRAI (JG), the IPR sponsor. PRAI, a nonprofit organization supported by the parent/patient
93 community raised funds from families affected by PANS and related conditions to fund the creation of the IPR, the first
94 registry for families affected by PANS and related conditions. Through social media platforms, thousands of families
95 affected by PANS from around the world contributed to the development of the IPR survey content. These efforts reflect
96 the patient community's commitment to the project and their confidence that the IPR could accelerate research and
97 elucidate the barriers to children receiving timely and appropriate diagnoses and treatment.

98 **Participants**

99 The target population for the IPR is children, adolescents, and adults in the U.S. and Canada with PANS-like
100 neuroimmune conditions (cases) and their siblings who were not believed to be affected by these conditions at the time
101 of enrollment. Enrollment in the IPR is ongoing and open to the general public via the IPR's website
102 (www.pansregistry.org). Adult caregivers enroll and respond to all survey questions for their child(ren) less than 18 years
103 of age or who are adults for whom the caregiver has a formal Power of Attorney.

104 **Eligibility criteria**

105 We invited families who believe their previously healthy children, who did not have chronic neurological and psychiatric
106 problems, developed PANS-like features they believe are related to an immune response, irrespective of a PANS
107 diagnosis by a clinician. Individuals in recovery as well as those with active symptoms at the time of enrollment are
108 eligible. We did not restrict IPR enrollment eligibility to the current PANS working criteria (1,4). Given that PANDAS is
109 considered a subgroup of PANS (4), individuals suspected of having PANDAS are included in the study population. We
110 intentionally cast a wide net for inclusion to capture those with milder symptoms and insidious onsets to generate a
111 large recruitment pool by which immune-mediated neuropsychiatric health may be broadly studied. To this end, we also

It is made available under a [CC-BY 4.0 International license](#) .

112 included siblings who have not experienced any PANS-related early signs or symptoms based on the knowledge that
113 cases cluster in families/ genetic component.

114 To focus on those with conditions that lack a diagnostic biomarker and are not classified as a known illness or disease,
115 participants who had received an autoimmune encephalitis (AE) diagnosis *before* their reported onset of PANS
116 symptoms were not eligible to participate during the first enrollment phase (July 19, 2020 through December 2021); this
117 exclusion criteria was dropped for recruitment beginning on July 19, 2022 to accommodate the possibility that PANS has
118 been misdiagnosed as AE and to ensure we've included these individuals. We asked detailed questions about lab results
119 and the basis for diagnosis among those who report having AE so that discretion may be used on a case-by-case basis
120 regarding their inclusion in research studies based on the IPR database.

121 **Recruitment strategies**

122 We recruited patients by convenient sampling directing interested parties to the publicly accessible link on the IPR's
123 website, using Facebook, mailing lists (including emails and newsletters), partnerships with other non-profit
124 organizations, clinical referral networks, local community events, and international conferences. JG led these
125 recruitment efforts.

126 **Survey Development**

127 The IPR surveys originated from engagement between clinicians, researchers, and more than 1,500 members of the
128 online PANS parent community, led by JG. Some of the survey questions emerged from social media interactions and
129 informal polling in online parent support groups, which are platforms that have allowed thousands of families from
130 around the world to compare notes on common clinical reports, histories, symptom presentations, and treatment
131 responses they have observed in their children. EEM, an epidemiologist, worked with JG to organize and convert these
132 topics and questions into the set of surveys listed in Table 1, which comprise the baseline IPR data. During early 2020,
133 we conducted an iterative piloting process of the full set of surveys with the families of 100 volunteer cases and their
134 siblings.

135 Data elements

136 IPR’s baseline survey questions address the following topics: eligibility, demographics, maternal & child health (MCH),
137 patient’s current health status, comorbidities, and characteristics, and family health history. We collect additional
138 information on PANS/PANDAS cases, including details regarding onset, diagnoses, symptoms, flares in symptoms,
139 treatment experience, health care utilization, and school attendance (Table 1). We inquired about symptoms, family
140 health history, infectious disease exposure and immune dysregulation, and general medical history, guided by existing
141 PANS literature and patient advocate websites (1,4,31–33). We also designed our survey about treatment and
142 medication experience to align with clinical management approaches described by PANS experts in the literature.(34–
143 36) For questions that related to those asked in national surveys, including from the National Health and Nutrition
144 Examination Survey (NHANES) and the Pregnancy Risk Assessment Monitoring System (PRAMS) (37,38), we used the
145 same questions and response options as the national surveys to be able to make comparisons to national population
146 averages. To our knowledge, this study includes detailed data on certain topics that have not been formally collected
147 within this patient population. These questions originated from polls and discussions on patient support group social
148 media pages. The topics relate to phenotypic characteristics (maternal and child), maternal health, early life of the child
149 (pre-, peri-, and postnatal), and early disease experience.

150 **Table 1. Overview of baseline survey forms for the International PANS Registry**

Data collection form	Topics addressed
<i>introduction*</i>	family size and structure, adult/child participant, siblings, contact information, data sharing preferences
<i>household demographics*</i>	marital status, home ownership, home size, language, employment, income, education, household smoke exposure, home water damage
<i>eligibility</i>	name, date of birth, survey respondent details, disease status (“diagnosed” v. suspected case)
<i>individual demographics</i>	birth order, sex, education level, race, place of birth, income, neighborhood information
<i>maternal health</i>	maternal health conditions, diagnoses, and phenotypic traits and other characteristics
<i>pre-, peri-, and postnatal</i>	maternal pregnancy history, maternal health during pregnancy, maternal exposures, supplements,

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

<i>periods</i>	pregnancy complications, birth complications, birth anthropometrics, birth defects, postnatal feeding, developmental milestones/delays, infant health conditions, infant infection exposure
<i>comorbidities</i>	general and oral health assessment, dental health condition, body weight, food allergies, health conditions and diagnoses, infection exposure, significant medical events
<i>phenotypic traits and other characteristics</i>	skin tone, hair characteristics, eye color, IQ test scores, dominant hand, reaction to insect bites, skin abnormalities, characteristics related to skin/muscle/tissue, pain, the autonomic nervous system, and miscellaneous
<i>family health history</i>	nuclear biological family conditions/diseases, PANS/PANDAS in the nuclear and extended family
<i>onset**</i>	detailed assessment of acuity, evaluation by physician, symptoms, suspected triggers, place of residence, any chronic conditions
<i>diagnoses**</i>	PANS confirmation by a physician and related details, Cunningham Panel data, abnormal lab results, AE diagnosis details (if diagnosed)
<i>symptoms**</i>	Report of main PANS-related symptoms and subtypes of each, puberty status, known/related health conditions
<i>flares**</i>	typical frequency, duration, physician assessment, symptoms, suspected triggers, chronic status, remission status, seasonal pattern
<i>treatment/medication experiences**</i>	treatments/medications ever tried, reported alleviation and/or worsening of symptoms
<i>health care utilization & school attendance**</i>	Insurance coverage, estimated costs for PANS-related care, experience locating and accessing care, hospitalizations, mental health care, ability to attend school, schooling accommodations

* indicates household level measures (all others are individual)

** indicates cases only (all others are cases and siblings)

We ask parents to have their child’s medical records, including their vaccine record, clinical test results and lab reports, in hand so that they can accurately report these results in the survey forms. We also capture parent response for each of the current working criteria for PANS and PANDAS (4). The complete set of the first version of surveys constitutes more than 2,000 data fields for cases and more than 1,400 data fields for siblings. Complete data dictionaries describing the baseline survey data available may be found on the IPR website (<https://pansregistry.org/researchers/>).

159 **Data collection and storage**

160 IPR data collection began on July 19, 2020 on the Dacima Software Inc© platform. Data collection on this platform
161 concluded in December 2021. In July 2022, IPR data collection and management activities transitioned to the UW and
162 resumed on the Research Electronic Data Capture (REDCap) software platform supported by the UW's Institute of
163 Translational Health Sciences (ITHS) (39). REDCap (Research Electronic Data Capture) is a secure, web-based application
164 designed to support data capture for research studies, providing: 1) an intuitive interface for validated data entry; 2)
165 audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data
166 downloads to common statistical package; and 4) procedures for importing data from external sources.

167 The full set of original surveys (on the Dacima platform in 2020-2021) took 2-3 hours per case to complete. In 2022, the
168 baseline surveys were pared down when the survey platform transitioned to REDCap at the UW (40). Completing the full
169 set of this second version of baseline surveys takes less than one hour per case. On both platforms, participants were
170 allowed to save their work and continue in separate segments of time.

171 Until 2021, any participant who signed up (with their email contact) and provided (a) either name or date of birth and
172 (b) case/sibling status was included in the IPR Recruitment Pool. Beginning in 2022, participants may opt to sign up for
173 recruitment purposes *only* and are asked to complete a 15-minute survey per individual enrollee (includes variables
174 listed in Table 2). For those interested in more in-depth participation, embedded within the IPR is the IPR Epidemiology
175 Study, an observational, longitudinal study that will investigate the epidemiology of the broad spectrum of PANS
176 through a series of analyses and manuscripts led by IPR investigators (manuscript describing baseline characteristics
177 under review).

179 **Analytic plans**

180 IPR survey data will be used to describe clinical, phenotypic, and epidemiologic characteristics of participants and to
181 explore patterns in these characteristics across the IPR sample. The IPR team will analyze baseline survey data using SAS

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

version 9.4 (SAS Institute, Cary, NC, USA). We will clean the data and present descriptive statistics alongside detailed data documentation. In subsequent analyses, we will rely on regression models to evaluate relationships within the data. Analytic techniques to classify subgroups or identify clusters in the data will include latent class analysis and supervised and unsupervised machine learning approaches. We will apply appropriate evaluation metrics depending on the model type. We will consider p-values <0.05 and/or 95% confidence intervals not including 0 value as “statistically significant” and will correct for multiple testing when appropriate.

Ancillary study subsample selection

Collaborators may target a subsample of the IPR for ancillary study recruitment by applying various criteria to identify narrow, homogenous, and moderate/severe participant subgroups. Table 2 lists survey questions that describe participant diagnoses, symptom onset characteristics, and treatment/medication attempts. While we expect these to be the most commonly relied upon selection criteria, all variables listed in Table 1 above may also be utilized for sample selection purposes.

Table 2. Parent-reported variables available for ancillary study sample selection from the International PANS Registry

Variable	Response options
Has your child (1) ever been diagnosed with PANS or PANDAS and/or (2) do you BELIEVE they have/had PANS or PANDAS?	Yes, PANS / Yes, PANDAS / Yes, both / Yes, but I’m not sure which one / No, I am enrolling my child as a sibling
Has a physician formally diagnosed your child with PANS or PANDAS?	Yes / No → If “Yes”: PANS/PANDAS/both
What do you suspect your child has? Please select all that apply.	PANS/PANDAS/both
Would you say your child's PANS onset was:	Sudden and dramatic / A gradual progression
Do you feel like you can pinpoint the day or week symptoms began?	Yes / No
If reported onset was “Sudden and dramatic”:	
How old was your child (in years) at the time of sudden and dramatic onset?	[integer]

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Over what duration of time did his or her dramatic increase in PANS symptoms develop?	24-72 hours / 3 days–1 week / 1-3 weeks / 3-6 weeks / 6 weeks-3 months / 3-9 months / > 9 months
Would you say your child was ever symptom-free?	Yes / No
In hindsight, do you think your child showed any early signs or symptoms of having PANS?	Yes / No
Looking back, how old (in years) was your child when you first noticed early signs or symptoms of PANS? (Please enter '0' for less than 1 year of age)	[integer]
If reported onset was “A gradual progression”:	
Looking back, how old (in years) was your child when you first noticed early signs or symptoms of PANS? (Please enter '0' for less than 1 year of age)	[integer]
Would you say your child was ever symptom-free?	Yes / No
Did your child experience a dramatic increase in PANS symptoms at some point?	Yes / No
How old was your child (in years) at the time of the dramatic increase in PANS symptoms?	[integer]
Over what duration of time did his or her dramatic increase in PANS symptoms develop?	24-72 hours / 3 days–1 week / 1-3 weeks / 3-6 weeks / 6 weeks-3 months / 3-9 months / > 9 months
Please select all neuropsychiatric symptoms that your child has experienced	Obsessions (unwanted thoughts, fears, and recurring worries) / Compulsions (repetitive behaviors and rituals) / Severe restriction of food intake / Unexpected increase in food intake / Body-Focused Repetitive Behaviors (BFRB) (including hair pulling, skin picking, nail biting) / Anxiety (including separation anxiety, irrational fears) / Emotional lability (including mood changes, depression) / Selective Mutism / Irritability, aggression, severe oppositional behaviors / Behavioral (developmental) regression (including "baby talk", temper tantrums and "clingyness") / Deterioration in school

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

	performance (including deficit of certain skills, shortened attention span) / Sensory abnormalities (including unusual sensitivity of the senses) / Motor abnormalities (including tics, clumsiness, motoric hyperactivity, speech disorders) / Somatic signs and symptoms (including sleep disturbance and urinary symptoms) / Other
Did any of these symptoms begin following a known streptococcal infection?	Yes / I'm not sure / No
Can these symptoms be explained by a known neurologic or medical disorder, such as Sydenham chorea, systemic lupus erythematosus, Tourette disorder, or others?	Yes / No
Did any of these symptoms affect your child before puberty?	Yes / No
Do you consider your child to be in remission (symptom free) now?	No / Yes, with ongoing treatment/medications / Yes, without any treatment/medications
Comorbidities and diagnoses	<p>Immune-related:</p> <p>Alopecia areata (hair loss, often in clumps) / Asthma / Autoimmune encephalitis (AE) / Celiac disease / Eczema / Hashimoto's disease / Inflammatory bowel disease (IBD) / Lupus / Mast cell activation syndrome (MCAS) / Psoriasis / Postural orthostatic tachycardia syndrome (POTS) / Raynaud's disease / Sydenham Chorea (SC) / Primary immunodeficiency diseases (PID), not listed above / other / none of the above</p> <p>Other:</p> <p>Anorexia or Avoidant/restrictive food intake disorder (ARFID) / Anxiety / Attention-deficit/hyperactivity disorder (ADHD) or Attention Deficit Disorder (ADD) / Autism Spectrum Disorders (ASDs), including Asperger's syndrome / concussion / Conversion disorder / Dyslexia / Eosinophilic Esophagitis or Gastritis / Hypothyroid / Mood disorder / Obsessive-</p>

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

	compulsive disorder (OCD) / Oppositional defiant disorder (ODD) / seizures / Sensory Processing Disorder (SPD) / Pervasive developmental disorders (PDD) / Tourette Syndrome (TS) / other Tic disorders (not Tourette's) / other / none of the above
Treatments and medications ever tried and effect	antibiotics (oral administration) / antibiotics (intravenous (IV) administration) / antifungals / antivirals / oral nonsteroidal anti-inflammatory drugs (NSAID) / corticosteroids / Intravenous immune globulin (IVIG) / Subcutaneous Immunoglobulin (SCIg) / monoclonal antibody therapy (e.g., Rituximab) / Plasmapheresis / Psychotropic medications (including selective serotonin) / Cognitive behavior therapy (CBT) / supplements / antihistamines (H1 and H2 blockers) / diet modification / homeopathy / tonsillectomy or adenoidectomy / "tincture of time" (wait it out) / none of the above

196

197 **Ethics and dissemination**

198 Data collection activities in 2020 and 2021 were approved by the IntegReview (now Avarra) Institutional Review Board
199 (IRB) (#PRAI_svy001) for U.S. and Canadian citizens. Beginning in 2022, data collection activities were additionally
200 approved by the University of Washington (UW) IRB (#STUDY00014294) for U.S. citizens. All participants have consented
201 via an e-signature on survey software platforms to be followed longitudinally and indefinitely, to receive invitations to
202 participate in ancillary studies, and to share their de-identified data. De-identified data from the IPR are available to the
203 public via an online data request portal (<https://pansregistry.org/researchers/>).

204 **Status of the IPR recruitment pool**

205 At the end of 2021, the IPR had registered 3,247 children from 1,666 households. Enrollment remains open. These
206 participants included cases and their healthy siblings. Most of the 1,666 households enrolled reported having one to

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

three children (94%). To date, participating households are from all regions of the U.S. and Canada but are not evenly distributed.

Discussion

To date, the IPR has registered 1,666 families (3,247 children) and is the largest database in the world that gathers in-depth information on children with PANS and PANS-like features and their siblings. This database will serve as a translational health tool for conducting studies that address unresolved research questions around immune-mediated neuropsychiatric conditions related to PANS. The selection criteria for IPR enrollment are intentionally less restrictive than the current working criteria for PANS to generate a large recruitment pool and enable study of the broad spectrum of PANS-like conditions using big data analytics and tracking patients over time. Current limitations of the IPR include that the survey data is based on parental self-report and subject to recall bias. The convenient sample of participants is not generalizable or representative of any region, demographic, nor specific patient population.

In the long term, the IPR hopes to contribute to improving patient care, public health, and policy related to PANS by providing a tool for developing biology-based diagnoses, treatments, screening and surveillance. The IPR maintains open enrollment and is designed to enable ancillary study recruitment based on detailed selection criteria and to grow and expand in scope in the future (e.g., enroll study controls, integrate medical record information, collect biospecimens). To this end, the IPR team is also committed to data sharing. De-identified data from the IPR are available to the public via an online data request portal (<https://pansregistry.org/researchers/>). Complete data dictionaries describing the survey data available may also be found at this site. Participant data is kept confidential. The data is coded with a non-identifying subject ID. The Registry is intended to serve as a recruitment tool for new studies. We invite researchers to design studies that leverage existing data from the IPR database and extend knowledge in an area beyond the original scope of the IPR, including but not limited to immunology, rheumatology, microbiology, psychiatry, neurology, and genetics.

231 **Author Contributions**

232 EEM and JG jointly conceptualized the IPR. EEM acquired ethics approvals and led the survey design and writing of the
233 original draft of this manuscript. JG contributed to designing the surveys and was responsible for acquisition of funding,
234 study participant recruitment, and contributed to reviewing and editing this manuscript. Both authors have read and
235 approve of this final version of the manuscript for publication.

236 **Acknowledgements**

237 The authors thank the participating families for their dedicated time and commitment to their community goal of
238 building the IPR. We appreciate the input of those who helped inform our survey design, the time of those who shared
239 their children's health information, and the many contributions of those who supported the fundraising effort to
240 support this project. We specifically thank the Neuroimmune Foundation for their key contributions to our recruitment
241 efforts. We would like to acknowledge the support of Dacima Software Inc©, the survey platform on which the first
242 wave of data reported here was collected.

243 **Funding**

244 This study was funded by the Pediatric Research & Advocacy Initiative (PRAI; <https://praikids.org/>), a 501c3 nonprofit
245 organization founded by the patient community. REDCap, the survey platform being used to collect and manage study
246 data, at ITHS is supported by the National Center for Advancing Translational Sciences of the National Institutes of
247 Health under Award Number UL1 TR002319.

248 **Competing interests**

249 Authors declare no competing interests

250 **Ethics approval**

It is made available under a [CC-BY 4.0 International license](#) .

251 Data collection activities in 2020 and 2021 were approved by the IntegReview (now Avarra) Institutional Review Board
252 (IRB) (#PRAI_svy001) for U.S. and Canadian citizens. Starting in 2022, data collection activities were approved by the UW
253 IRB (#STUDY00014294) for U.S. citizens.

254 **Data availability statement**

255 The IPR team is committed to data sharing. De-identified data from the IPR are available to the public via an online data
256 request portal and subject to an approval process (<https://pansregistry.org/researchers/>). Participant data is kept
257 confidential. The data is coded with a non-identifying subject ID. Complete data dictionaries describing the survey data
258 available may also be found at this site. The Registry is also intended to serve as a recruitment tool for new studies.

259 Please contact the study PI and lead author of this manuscript to further discuss interest (emaster@uw.edu).

260 Informed consent documentation may be made available upon request. Participants who provided their email address
261 upon enrollment consented to be contacted in the future with messages/updates and subsequent data collection
262 requests from the IPR and, potentially, other researchers who would like to select a study sample from the IPR
263 recruitment pool. The data they provided when they enrolled in the IPR may be used for future studies and recruitment
264 purposes (i.e., study inclusion criteria). We allow participants to select specific permissions for the type of third party
265 with whom they wish their data be shared with when they enroll and will select data accordingly for outside requests.

266 **Collaborators**

267 The IPR team invites external collaborative research proposals to use the IPR database for analyses and recruitment.

268

269

270

References

271

- 272 1. Chang K, Frankovich J, Cooperstock M, Cunningham MW, Latimer ME, Murphy TK, et al. Clinical Evaluation of Youth
273 with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus
274 Conference. *J Child Adolesc Psychopharmacol*. 2015 Feb;25(1):3–13.
- 275 2. Murphy TK, Gerardi DM, Leckman JF. Pediatric Acute-Onset Neuropsychiatric Syndrome. *Psychiatr Clin N Am*.
276 2014;37:353–74.
- 277 3. Murphy TK, Patel PD, McGuire JF, Kennel A, Jane Mutch P, Carla Parker-Athill E, et al. Characterization of the
278 Pediatric Acute-Onset Neuropsychiatric Syndrome Phenotype. *J Child Adolesc Psychopharmacol*. 2015;25(1):14–25.
- 279 4. Swedo S. From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to Describe PANS (Pediatric
280 Acute-onset Neuropsychiatric Syndrome). *Pediatr Ther [Internet]*. 2012 [cited 2022 May 11];02(02). Available from:
281 [https://www.omicsonline.org/from-research-subgroup-to-clinical-syndrome-modifying-the-pandas-criteria-to-](https://www.omicsonline.org/from-research-subgroup-to-clinical-syndrome-modifying-the-pandas-criteria-to-describe-pans-pediatric-acute-onset-neuropsychiatric-syndrome-2161-0665.1000113.php?aid=4020)
282 [describe-pans-pediatric-acute-onset-neuropsychiatric-syndrome-2161-0665.1000113.php?aid=4020](https://www.omicsonline.org/from-research-subgroup-to-clinical-syndrome-modifying-the-pandas-criteria-to-describe-pans-pediatric-acute-onset-neuropsychiatric-syndrome-2161-0665.1000113.php?aid=4020)
- 283 5. PANDAS Network [Internet]. [cited 2022 Jun 9]. Research Priorities: PANDAS/PANS Roadmap To A Cure. Available
284 from: <https://pandasnetwork.org/research-priorities-pandas-pans-roadmap-to-a-cure/>
- 285 6. Murphy TK, Gerardi DM, Leckman JF. Pediatric Acute-Onset Neuropsychiatric Syndrome. *Psychiatr Clin North Am*.
286 2014 Sep;37(3):353–74.
- 287 7. Hedderly T, Malik O. Childhood Acute Neuropsychiatric Syndromes...furthering the discussion PANS and PANDAS.
288 *Eur J Paediatr Neurol*. 2018 Mar;22(2):223–4.
- 289 8. Murphy TK, Patel PD, McGuire JF, Kennel A, Mutch PJ, Parker-Athill EC, et al. Characterization of the Pediatric Acute-
290 Onset Neuropsychiatric Syndrome Phenotype. *J Child Adolesc Psychopharmacol*. 2015 Feb;25(1):14–25.
- 291 9. Chang K, Frankovich J, Cooperstock M, Cunningham MW, Latimer ME, Murphy TK, et al. Clinical Evaluation of Youth
292 with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus
293 Conference. *J Child Adolesc Psychopharmacol*. 2015 Feb;25(1):3–13.
- 294 10. Frankovich J, Leibold CM, Farmer C, Sainani K, Kamalani G, Farhadian B, et al. The Burden of Caring for a Child or
295 Adolescent With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): An Observational Longitudinal Study. *J*
296 *Clin Psychiatry [Internet]*. 2018 Dec 11 [cited 2022 May 24];80(1). Available from:
297 <https://www.psychiatrist.com/JCP/article/Pages/2019/v80/17m12091.aspx>
- 298 11. Pérez-Vigil A, Fernández de la Cruz L, Brander G, Isomura K, Gromark C, Mataix-Cols D. The link between
299 autoimmune diseases and obsessive-compulsive and tic disorders: A systematic review. *Neurosci Biobehav Rev*.
300 2016 Dec;71:542–62.
- 301 12. Frankovich J, Thienemann M, Rana S, Chang K. Five Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome of
302 Differing Etiologies. *J Child Adolesc Psychopharmacol*. 2015 Feb;25(1):31–7.
- 303 13. Swedo SE. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with
304 streptococcal infections by a marker associated with rheumatic fever. *Am J Psychiatry*. 1997 Jan;154(1):110–2.
- 305 14. Swedo SE, Seidlitz J, Kovacevic M, Latimer ME, Hommer R, Lougee L, et al. Clinical Presentation of Pediatric
306 Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections in Research and Community
307 Settings. *J Child Adolesc Psychopharmacol*. 2015 Feb;25(1):26–30.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

- 308 15. Swedo SE, Mittleman B, Lougee L. Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal
309 Infections: Clinical Description of the First 50 Cases. *Am J Psychiatry*. 1998;8.
- 310 16. Brown K, Farmer C, Farhadian B, Hernandez J, Thienemann M, Frankovich J. Pediatric Acute-Onset Neuropsychiatric
311 Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-
312 Based PANS Clinic. *J Child Adolesc Psychopharmacol*. 2017 Sep 1;27(7):629–39.
- 313 17. Leckman JF, King RA, Gilbert DL, Coffey BJ, Singer HS, Dure LS, et al. Streptococcal Upper Respiratory Tract Infections
314 and Exacerbations of Tic and Obsessive-Compulsive Symptoms: A Prospective Longitudinal Study. *J Am Acad Child
315 Adolesc Psychiatry*. 2011 Feb 1;50(2):108-118.e3.
- 316 18. Murphy TK, Sajid M, Soto O, Shapira N, Edge P, Yang M, et al. Detecting pediatric autoimmune neuropsychiatric
317 disorders associated with streptococcus in children with obsessive-compulsive disorder and tics. *Biol Psychiatry*.
318 2004 Jan 1;55(1):61–8.
- 319 19. Leslie DL, Kozma L, Martin A, Landeros A, Katsovich L, King RA, et al. Neuropsychiatric Disorders Associated with
320 Streptococcal Infection: A Case-Control Study among Privately Insured Children. *J Am Acad Child Adolesc Psychiatry*.
321 2008 Oct;47(10):1166–72.
- 322 20. Lewin AB, Storch EA, Murphy TK. Pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in
323 identical siblings. *J Child Adolesc Psychopharmacol*. 2011;21:177–82.
- 324 21. Stanford Medicine. PANS: Pediatric Acute-onset Neuropsychiatric Syndrome. [cited 2022 May 24]. Q & A; PANS:
325 Pediatric Acute-onset Neuropsychiatric Syndrome. Available from: [https://med.stanford.edu/pans/about/Q-and-
326 A.html](https://med.stanford.edu/pans/about/Q-and-A.html)
- 327 22. Chan A, Phu T, Farhadian B, Willett T, Thienemann M, Frankovich J. Familial Clustering of Immune-Mediated
328 Diseases in Children with Abrupt-Onset Obsessive Compulsive Disorder. *J Child Adolesc Psychopharmacol*. 2020 Jun
329 1;30(5):345–6.
- 330 23. Mataix-Cols D, Frans E, Pérez-Vigil A, Kuja-Halkola R, Gromark C, Isomura K, et al. A total-population
331 multigenerational family clustering study of autoimmune diseases in obsessive-compulsive disorder and
332 Tourette's/chronic tic disorders. *Mol Psychiatry*. 2018 Jul;23(7):1652–8.
- 333 24. Horvath RS, Keating S. Patient-Driven Findings of Genetic Associations for PANS and PANDAS. *J Biomed Transl Res*.
334 2021 Dec 31;7(3):116–22.
- 335 25. Trifiletti R, Lachman HM, Manusama O, Zheng D, Spalice A, Chiurazzi P, et al. Identification of ultra-rare genetic
336 variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing. *Sci
337 Rep*. 2022 Jun 30;12:11106.
- 338 26. He H, Yu Y, Liew Z, Gissler M, László KD, Valdimarsdóttir UA, et al. Association of Maternal Autoimmune Diseases
339 With Risk of Mental Disorders in Offspring in Denmark. *JAMA Netw Open*. 2022 Apr 15;5(4):e227503.
- 340 27. Estes ML, McAllister AK. Maternal immune activation: Implications for neuropsychiatric disorders. *Science*. 2016 Aug
341 19;353(6301):772–7.
- 342 28. Lombardo MV, Moon HM, Su J, Palmer TD, Courchesne E, Pramparo T. Maternal immune activation dysregulation of
343 the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. *Mol Psychiatry*.
344 2018 Apr;23(4):1001–13.
- 345 29. International PANS Registry | International PANS Registry [Internet]. [cited 2022 May 24]. Available from:
346 <https://pansregistry.org/>

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

- 347 30. Neuroimmune_Conf2021_IPR_Masterson.pdf [Internet]. [cited 2022 May 24]. Available from:
348 https://www.neuroimmune.org/wp-content/uploads/2021/05/Neuroimmune_Conf2021_IPR_Masterson.pdf
- 349 31. Aspire [Internet]. [cited 2022 Jun 9]. PANS PANDAS Symptoms: A unique set of symptoms. Available from:
350 <https://aspire.care/symptoms-diagnosis/symptoms/>
- 351 32. What are PANS and PANDAS? Neuroimmune Disorders | Neuroimmune [Internet]. Neuroimmune Foundation.
352 [cited 2022 Jun 9]. Available from: <https://neuroimmune.org/what-are-pans-pandas/>
- 353 33. PANDAS Network [Internet]. [cited 2022 Jun 9]. Understanding PANDAS. Available from:
354 <https://pandasnetwork.org/understanding-pandas/>
- 355 34. Swedo SE, Frankovich J, Murphy TK. Overview of Treatment of Pediatric Acute-Onset Neuropsychiatric Syndrome. J
356 Child Adolesc Psychopharmacol. 2017 Sep;27(7):562–5.
- 357 35. Frankovich J. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II—Use of
358 Immunomodulatory Therapies. J Child Adolesc Psychopharmacol. 2017;27(7):574–93.
- 359 36. Thienemann M, Murphy T, Leckman J, Shaw R, Williams K, Kapphahn C, et al. Clinical Management of Pediatric
360 Acute-Onset Neuropsychiatric Syndrome: Part I—Psychiatric and Behavioral Interventions. J Child Adolesc
361 Psychopharmacol. 2017 Sep;27(7):566–73.
- 362 37. NHANES - National Health and Nutrition Examination Survey Homepage [Internet]. 2022 [cited 2022 May 31].
363 Available from: <https://www.cdc.gov/nchs/nhanes/index.htm>
- 364 38. Pregnancy Risk Assessment Monitoring System | CDC [Internet]. 2022 [cited 2022 May 31]. Available from:
365 <https://www.cdc.gov/prams/index.htm>
- 366 39. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research Electronic Data Capture (REDCap) - A
367 metadata-driven methodology and workflow process for providing translational research informatics support. J
368 Biomed Inform. 2009 Apr;42(2):377–81.
- 369 40. Cassidy LD. REDCap and clinical registries as a platform to promote clinical translational research. In: Translational
370 Medicine [Internet]. Chicago, IL, USA: Translational Medicine; 2013 [cited 2022 May 31]. p. 179. Available from:
371 https://www.omicsonline.org/2161-1025/2161-1025-Translational-2013_AcceptedAbstracts.digital

372

373

374